Back to results
US 2010/0061980 A1Published application
Assays to predict and monitor antibody mediated rejection of transplanted allografts
AssigneeCedars-Sinai Medical Center
InventorMieko Toyoda
Life of this patent
Estimating the term…
Abstract
The present invention is directed to assays that may be used to measure B cell reactivity to allo or donor antigens in patients, gauge the efficacy of desensitization treatment of these individuals, predict antibody mediated rejection, and monitor patients post transplant for antibody mediated rejection.
Claims32
A method for the detection of allo- or donor-specific B cells in a patient comprising:
- (a) treating a sample of blood from the patient with at least one co-stimulating antibody and a Golgi body secretion inhibitor to form a treated sample;
- (b) adding challenge antigens to the treated sample to form a challenged sample;
- and
- (c) analyzing the challenged sample and a control sample to detect IFNγpositive B cells;
- whereby an increase in the number of IFNγpositive B cells in a challenged sample as compared to a control sample is indicative of B cell activation.
2 more elements
A method of preventing antibody mediated rejection of a transplanted organ in a patient in need thereof, the method comprising:
- (a) treating a sample of blood from the patient with at least one co-stimulating antibody and a Golgi body secretion inhibitor to form a treated sample;
- (b) adding challenge antigens to the treated sample to form a challenged sample;
- (c) analyzing the challenged sample and a control sample to detect IFNγpositive
- B cells;
- whereby an increase in the number of IFNγpositive B cells in a challenged sample as compared to a control sample is indicative of B cell activation;
- and
- (d) correlating the presence of allo- or donor-specific B cells with a likelihood that the patient will undergo antibody mediated graft rejection or chronic rejection.
4 more elements
A diagnostic method comprising:
- (a) obtaining a sample of blood from a patient;
- (b) treating the sample of blood with at least one co-stimulating antibody and a Golgi body secretion inhibitor to form a treated sample;
- (c) adding challenge antigens to the treated sample to form a challenged sample;
- (d) analyzing the challenged sample and a control sample to detect IFNγpositive B cells;
- whereby an increase in the number of IFNγpositive B cells in a challenged sample as compared to a control sample is indicative of B cell activation;
- and
- (e) providing a report of the analyzed results comprising the level of allo- or donor-specific B cells in the patient.
4 more elements
Dependencies are inferred from the claim text.